## SOLV: Solventum Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0); RSI 81 overbought. Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.5% MRS), overbought RSI (81).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($81.51)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Solventum stock rating upgraded to Buy at BTIG on improved execution By Investing.com**
- Source: Investing.com Nigeria | 20251202T122600 | Bullish | Relevance: 99%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and overcoming initial challenges faster than expected for the healthcare spin-out. The upgrade reflects optimism about Solventum's top-line growth and increased margins, supported by recent divestitures and acquisitions. Despite a recent EPS miss, the company's strategic moves, including the acquisition of Acera Surgical and a share repurchase program, are expected to drive future growth and shareholder value.

**2. Solventum stock rating upgraded to Buy at BTIG on improved execution**
- Source: Investing.com Nigeria | 20251202T122600 | Bullish | Relevance: 99%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and a positive outlook for the healthcare spin-out. The upgrade reflects Solventum's success in overcoming initial challenges, reducing debt through a business divestiture, and its consistent performance against guidance. The company's recent acquisition plans and share repurchase program are also highlighted as positive strategic moves.

**3. Solventum stock rating upgraded to Buy at BTIG on improved execution**
- Source: Investing.com | 20251202T062500 | Bullish | Relevance: 98%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and a stronger outlook for 2026. This upgrade reflects the company's faster-than-expected resolution of initial challenges, debt reduction through divestiture, and consistent performance against guidance, despite a recent EPS miss. The company also announced plans to acquire Acera Surgical and a $1 billion share repurchase program.

**4. Solventum stock rating upgraded to Buy at BTIG on improved execution**
- Source: Investing.com India | 20251202T165600 | Bullish | Relevance: 98%
- BTIG upgraded Solventum (NYSE:SOLV) from Neutral to Buy, setting a price target of $100.00, citing improved execution and increased investor confidence following the company's divestiture of its Purification & Filtration business and consistent performance. The upgrade reflects BTIG's positive outlook on Solventum's top-line growth and expected margin increases, supported by 6 analysts revising earnings upwards. Despite a recent earnings miss in Q3 2025, Solventum's acquisition of Acera Surgical and a $1 billion share repurchase program signal strategic moves for market presence and shareholder value.

**5. Here Are Tuesday's Top Wall Street Analyst Research Calls: Albemarle, Circle Internet, Cloudflare, Danaher, Inspire Medical, Six Flags, Workday and More**
- Source: 24/7 Wall St. | 20251202T131551 | Somewhat-Bullish | Relevance: 72%
- This article provides an overview of market performance on Monday, December 1st, 2025, noting a "risk off" session with all major indices closing lower, and highlights key movements in futures, bonds, oil and gas, gold, and cryptocurrencies. It then details top Wall Street analyst upgrades, downgrades, and initiations for several companies, including Albemarle, Six Flags, Inspire Medical Systems, Circle Internet Group, Cloudflare, Danaher, and Workday, among others, for Tuesday, December 2nd, 2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | BTIG | $100 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | BTIG | up | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 0 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+5.3%)
- Independent Franchis: 7.4% (+27.2%)
- Blackrock Inc.: 5.9% (+6.1%)
- Trian Fund Managemen: 4.9% (0.0%)
- State Street Corpora: 3.6% (+1.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 13.5x stretched relative to 5% growth. Quality metrics strong (ROE 37%, margin 18%). Institutional flow bullish (8 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.2B |
| Beta | 1.00 |
| 52W Range | $60.70 - $88.20 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 13.5 |
| Current P/E | 14.2 |
| YoY Growth | 5.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 7.5% to 1.0% (-6.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 (-0.6%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.96), confirming momentum. RSI overbought at 81, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.98% (CS: 78) | Neutral |
| RSI_14 | 81.0 | Overbought |
| MACD Histogram | 0.96 | Bullish |
| vs SMA20 | 1.106x | Above |
| vs SMA50 | 1.156x | Above |
| vs SMA200 | 1.169x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $85.59
- **Stop Loss:** $81.51 (4.8% risk)
- **Target:** $89.67 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 245
- **Position Value:** $20,969.55
- **Portfolio %:** 20.97%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-26 (Est: $1.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.43 | $1.50 | +4.7% |
| 2025Q2 | $1.45 | $1.69 | +16.2% |
| 2025Q1 | $1.22 | $1.34 | +9.7% |
| 2024Q4 | $1.31 | $1.41 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*